Additional file 1 of The Alzheimer’s disease drug development landscape

  • Sasja Heetveld (Contributor)
  • P. Scheltens (Contributor)
  • Prisca S. Leferink (Contributor)
  • Jeffrey Cummings (Contributor)
  • L. Vermunt (Contributor)
  • Pieter van Bokhoven (Contributor)
  • Everard G. B. Vijverberg (Contributor)
  • Arno de Wilde (Contributor)

Dataset / Software

Description

Additional file 1 : Table S1. Number of drugs in preclinical (pre) and clinical (clin) development for AD, stratified by target class and treatment modality.
Date made available1 Jan 2021
Publisherfigshare Academic Research System

Cite this